The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008In Vivo Assessment of Alpha-Synuclein Secretion
Objective/Rationale:
The pathophysiological roles of the secreted AS forms remain largely unknown. We have identified oligomeric and monomeric AS species in the conditioned medium (CM) of SHSY5Y cells... -
Rapid Response Innovation Awards, 2008Structural Mapping and Drug Design for Prevention and Treatment of Parkinson's Disease
Objective/Rationale:
Drugs for treating Parkinson's disease have to date been identified by trial and error. We are using protein structure as a guide for identifying potential drug targets for... -
Rapid Response Innovation Awards, 2008A Pore-Based Method to Sort and Characterize Human Embryonic Stem Cell-Derived Dopaminergic Neurons
Objective/Rationale:
Although using human Embryonic Stem Cells (hESCs) as a clinical therapy for Parkinson’s disease is extremely promising, there exists a number of technical obstacles. In particular... -
Rapid Response Innovation Awards, 2008Calpain Inhibitors to treat Parkinsons Disease
Objective/Rationale:
Activation of the calcium activated protease, calpain, has been implicated in the initiation of the process of neuronal degeneration associated with PD. Thus, inhibition of... -
Rapid Response Innovation Awards, 2008Measuring Metabolism of Alpha-synuclein in Extracellular Fluids
Objective/Rationale:
Accumulation of the alpha-synuclein protein inside neurons in particular regions of the brain is one of the hallmarks of Parkinson’s disease. Studies suggest that lowering the... -
Rapid Response Innovation Awards, 2008Exploring LRRK2 Substrate(s) for Parkinson Disease by Protein Arrays
Objective/Rationale:
Mutations in the leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of PD. A major gap in our understanding of how LRRK2 causes PD is the lack of knowledge of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.